ArticleBioactive materials2026
Single-cell and longitudinal transcriptomics-guided engineering of FZD1-targeting precision nanotherapy against osteosarcoma cancer stem cells.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most prevalent primary malignant bone tumor in children and adolescents. Osteosarcoma cancer stem cells (OCSCs) critically drive tumorigenesis and progression through their self-renewal capacity and therapy resistance. Understanding mechanisms maintaining OCSC stemness and identifying key therapeutic targets are thus critical for effective intervention. Here, we systematically analyzed OCSC transcriptomic features using single-cell and longitudinal RNA-sequencing, identifying transcription factor 7 like 1 (TCF7L1)-associated transcriptional activity in relation to OCSC stemness and frizzled class receptor 1 (FZD1)-associated Wnt/β-catenin signaling as a putative upstream pathway. FZD1 expression significantly correlated with clinical malignancy progression in osteosarcoma. Leveraging these transcriptional signatures, we screened and validated homoharringtonine as a potent therapeutic agent against osteosarcoma and OCSCs. To enhance efficacy while reducing systemic toxicity, an FZD1-targeted, pH/glutathione dual-responsive nanoplatform was engineered to achieve precise drug delivery to OCSC-derived tumors via high-affinity binding of UM206 peptide to FZD1, concurrently enabling tumor microenvironment-triggered homoharringtonine release in acidic, glutathione-rich niches. This integrated approach characterizes OCSC-associated transcriptional regulation and supports further development of OCSC-targeted precision nanotherapies for osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.